IMAB
Price
$4.38
Change
+$0.03 (+0.69%)
Updated
Sep 5 closing price
Capitalization
357.67M
67 days until earnings call
LYRA
Price
$6.85
Change
-$0.19 (-2.70%)
Updated
Sep 5 closing price
Capitalization
11.26M
Interact to see
Advertisement

IMAB vs LYRA

Header iconIMAB vs LYRA Comparison
Open Charts IMAB vs LYRABanner chart's image
I-MAB
Price$4.38
Change+$0.03 (+0.69%)
Volume$1.2M
Capitalization357.67M
Lyra Therapeutics
Price$6.85
Change-$0.19 (-2.70%)
Volume$14.03K
Capitalization11.26M
IMAB vs LYRA Comparison Chart in %
Loading...
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IMAB vs. LYRA commentary
Sep 08, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IMAB is a StrongBuy and LYRA is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 08, 2025
Stock price -- (IMAB: $4.38 vs. LYRA: $6.85)
Brand notoriety: IMAB and LYRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IMAB: 50% vs. LYRA: 52%
Market capitalization -- IMAB: $357.67M vs. LYRA: $11.26M
IMAB [@Biotechnology] is valued at $357.67M. LYRA’s [@Biotechnology] market capitalization is $11.26M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IMAB’s FA Score shows that 0 FA rating(s) are green whileLYRA’s FA Score has 0 green FA rating(s).

  • IMAB’s FA Score: 0 green, 5 red.
  • LYRA’s FA Score: 0 green, 5 red.
According to our system of comparison, IMAB is a better buy in the long-term than LYRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IMAB’s TA Score shows that 5 TA indicator(s) are bullish while LYRA’s TA Score has 4 bullish TA indicator(s).

  • IMAB’s TA Score: 5 bullish, 5 bearish.
  • LYRA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, both IMAB and LYRA are a good buy in the short-term.

Price Growth

IMAB (@Biotechnology) experienced а +5.29% price change this week, while LYRA (@Biotechnology) price change was -2.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

IMAB is expected to report earnings on Nov 13, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IMAB($358M) has a higher market cap than LYRA($11.3M). IMAB YTD gains are higher at: 415.294 vs. LYRA (-33.624). LYRA has higher annual earnings (EBITDA): -35.34M vs. IMAB (-46.92M). IMAB has more cash in the bank: 169M vs. LYRA (29.8M). IMAB has less debt than LYRA: IMAB (3.68M) vs LYRA (32.5M). LYRA has higher revenues than IMAB: LYRA (770K) vs IMAB (0).
IMABLYRAIMAB / LYRA
Capitalization358M11.3M3,168%
EBITDA-46.92M-35.34M133%
Gain YTD415.294-33.624-1,235%
P/E RatioN/AN/A-
Revenue0770K-
Total Cash169M29.8M567%
Total Debt3.68M32.5M11%
TECHNICAL ANALYSIS
Technical Analysis
IMABLYRA
RSI
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
79%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
79%
Bullish Trend 3 days ago
86%
Momentum
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
84%
MACD
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
80%
Advances
ODDS (%)
Bullish Trend 5 days ago
77%
Bullish Trend 17 days ago
81%
Declines
ODDS (%)
Bearish Trend 10 days ago
88%
Bearish Trend 3 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
86%
View a ticker or compare two or three
Interact to see
Advertisement
IMAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LYRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
BTAFF54.22N/A
N/A
British American Tobacco p.l.c.
WILYY18.99N/A
N/A
Demant AS
CTYP6.30N/A
N/A
Community Bankers (PA)
PGCSF3.15N/A
N/A
Prosegur Cia De Securidad SA
SAVNF0.04N/A
-4.47%
SAVANNAH RESOURCES PLC

LYRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LYRA has been closely correlated with ROQAF. These tickers have moved in lockstep 85% of the time. This A.I.-generated data suggests there is a high statistical probability that if LYRA jumps, then ROQAF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LYRA
1D Price
Change %
LYRA100%
-2.70%
ROQAF - LYRA
85%
Closely correlated
N/A
EYPT - LYRA
58%
Loosely correlated
+17.93%
VERA - LYRA
54%
Loosely correlated
+10.46%
KYMR - LYRA
52%
Loosely correlated
+3.10%
CLNN - LYRA
39%
Loosely correlated
+1.34%
More